BioCryst presents new real-world data showing reduced attack rates in patients with HAE with normal C1-inhibitor

BioCryst presents new real-world data showing reduced attack rates in patients with HAE with normal C1-inhibitor following long-term treatment with Orladeyo (berotralstat)

BioCryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) leading to a reduction in monthly attack rates in patients with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH) level and function.

Dr Ryan Arnold, Chief Medical Officer of BioCryst, said: “There is a significant unmet need among people who live with HAE with normal C1-INH, and identifying optimal treatments has been challenging for these patients. These real-world observations suggest ORLADEYO can have a meaningful impact on the lives of people who have HAE with normal C1-INH. We look forward to continuing to evaluate our oral, once-daily prophylaxis as a treatment option for this subpopulation.”

The company also announced a new post-hoc analysis from the APeX-S clinical trial that showed a sustained reduction in HAE attacks compared to patients’ self-reported baseline attack rates.

The data were presented at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), which is being held at the Anaheim Convention Center in Anaheim, Calif., from 9-13 November 2023.

(Source: BioCryst)